SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1211)12/9/1997 10:15:00 PM
From: WWS  Read Replies (1) | Respond to of 2205
 
Marshall, As you do, I like to think that ATIS is a leader of the "skins" due to having aggressively pursued FDA approval for multiple indications: full and partial burns as well as diabetic foot ulcers. The fact that IART has pursued a more narrow niche (full-thickness burns) may help explain why their stock has lost 75% of its value in the past year. Bill (p.s. haven't heard about your "boards" results--ok, I hope).



To: Marshall Teitelbaum who wrote (1211)12/10/1997 1:05:00 AM
From: David S.  Read Replies (1) | Respond to of 2205
 
IART is one of many companies going after the reconstructive and burn markets. In the projections of the bulls on ATIS, my tummy tells me that the projections don't take into account the half dozen or so companies that are in clinicals going after the same areas as ATIS. As more companies get approvals, product pricing will become an issue also. The efficacy of ATIS product was described to me by a podiatrist.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News